Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GS-441524 in Healthy Subjects
NCT06274853Phase 1Withdrawn
- Sponsor
- National Center for Advancing Translational Sciences
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 1, randomised, double-blind trial of gs-441524 in coronavirus disease 2019 (COVID-19) (11 arms), sponsored by National Center for Advancing Translational Sciences. Primary endpoints: Treatment-emergent adverse events at 10 days, Blood Pressure at 10 days and 6 more. Planned start Jun 2024; status: withdrawn.
02
Drugs
gs-441524
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06274853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06274853.